Sanofi ADS$42.83MCK · NYSE
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $403.43B | $359.05B | $308.95B | $276.71B | $263.97B | $238.23B | $231.05B | $214.32B |
| Cost of Revenue | $388.88B | $345.73B | $296.12B | $264.35B | $250.84B | $226.08B | $219.03B | $202.56B |
| Gross Profit | $14.55B | $13.32B | $12.83B | $12.36B | $13.13B | $12.15B | $12.02B | $11.75B |
| Research & Development | — | — | — | — | — | — | $96.00M | $71.00M |
| Selling, General & Administrative | $8.10B | $8.51B | $8.66B | $7.78B | $10.54B | $8.85B | $9.18B | $8.44B |
| Operating Expenses | $8.34B | $8.90B | $8.92B | $7.98B | $11.09B | $17.19B | $9.53B | $10.87B |
| Operating Income | $6.21B | $4.42B | $3.91B | $4.38B | $2.04B | -$5.04B | $2.49B | $886.00M |
| Interest Expense | — | — | $252.00M | $248.00M | $178.00M | $217.00M | $249.00M | $264.00M |
| Other Income / (Expense) | $236.00M | $202.00M | $132.00M | $497.00M | $259.00M | $223.00M | $12.00M | $182.00M |
| Income Before Taxes | $6.20B | $4.36B | $3.79B | $4.63B | $1.93B | -$5.03B | $1.14B | $610.00M |
| Provision for Income Taxes | $1.10B | $878.00M | $629.00M | $905.00M | $636.00M | -$695.00M | $18.00M | $356.00M |
| Net Income | $4.76B | $3.29B | $3.00B | $3.56B | $1.11B | -$4.54B | $900.00M | $34.00M |
| Basic EPS | $38.55 | $25.86 | $22.54 | $25.23 | $7.32 | -$28.26 | $4.98 | $0.17 |
| Diluted EPS | $38.38 | $25.72 | $22.39 | $25.03 | $7.23 | -$28.26 | $4.95 | $0.17 |
| Basic Shares Outstanding | 123.60M | 127.40M | 133.20M | 141.10M | 152.30M | 160.60M | 180.60M | 196.30M |
| Diluted Shares Outstanding | 124.10M | 128.10M | 134.10M | 142.20M | 154.10M | 160.60M | 181.60M | 197.30M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Mar 2027 | $44.28 | $44.09 | $44.50 | 7 | ↑0 ↓0 |
| Mar 2028 | $49.96 | $49.56 | $50.43 | 7 | ↑1 ↓0 |
| Mar 2029 | $56.52 | $55.07 | $58.62 | 3 | ↑1 ↓0 |
| Mar 2030 | $61.22 | $61.22 | $61.22 | 1 | ↑1 ↓0 |
